News

Initiation of Phase I Part B

MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy...

read more

Equity and Loan Financing

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish...

read more

FP7 Grant

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. NeoStrep, a consortium consisting...

read more

Eurostar Grant

MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the...

read more

Danish Government Grant

MinervaX Announces the award of a 500,000 DKK (66,000 EUR) grant from the Ministry of Science, Technology and Innovation — “Videnkupon”. MinervaX, a private biotech company...

read more